Editas Medicine/$EDIT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Ticker
$EDIT
Sector
Primary listing
Employees
246
Headquarters
Website
Editas Medicine Metrics
BasicAdvanced
$254M
-
-$2.85
2.20
-
Price and volume
Market cap
$254M
Beta
2.2
52-week high
$3.90
52-week low
$0.91
Average daily volume
1.6M
Financial strength
Current ratio
2.772
Quick ratio
2.716
Long term debt to equity
78.112
Total debt to equity
110.141
Interest coverage (TTM)
-37.96%
Profitability
EBITDA (TTM)
-154.068
Gross margin (TTM)
-257.38%
Net profit margin (TTM)
-608.88%
Operating margin (TTM)
-413.35%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-33.76%
Return on equity (TTM)
-188.58%
Valuation
Price to revenue (TTM)
6.049
Price to book
12.89
Price to tangible book (TTM)
12.89
Price to free cash flow (TTM)
-1.148
Free cash flow yield (TTM)
-87.10%
Free cash flow per share (TTM)
-2.465
Growth
Revenue change (TTM)
-41.97%
Earnings per share change (TTM)
20.68%
3-year revenue growth (CAGR)
6.95%
10-year revenue growth (CAGR)
72.47%
3-year earnings per share growth (CAGR)
1.82%
10-year earnings per share growth (CAGR)
-22.45%
What the Analysts think about Editas Medicine
Analyst ratings (Buy, Hold, Sell) for Editas Medicine stock.
Editas Medicine Financial Performance
Revenues and expenses
Editas Medicine Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Editas Medicine stock?
Editas Medicine (EDIT) has a market cap of $254M as of September 17, 2025.
What is the P/E ratio for Editas Medicine stock?
The price to earnings (P/E) ratio for Editas Medicine (EDIT) stock is 0 as of September 17, 2025.
Does Editas Medicine stock pay dividends?
No, Editas Medicine (EDIT) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Editas Medicine dividend payment date?
Editas Medicine (EDIT) stock does not pay dividends to its shareholders.
What is the beta indicator for Editas Medicine?
Editas Medicine (EDIT) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.